Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: An eastern cooperative oncology group study (PB586)

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 23, Issue 4, 2000, Pages 371-375

  Kucuk, Omer ^a,b,c,d,e   Shevrin, Daniel H ^a,b,c,d   Pandya, Kishan J ^a,b,c,d   Bonomi, Philip D ^a,b,c,d  

^a WAYNE STATE UNIVERSITY   (United States)

^b EVANSTON HOSPITAL   (United States)

^c UNITY HEALTH SYSTEM   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e KARMANOS CANCER INSTITUTE   (United States)

Author keywords

5 Fluorouracil; Chemotherapy; Cisplatin; Etoposide; Non small cell lung cancer

Indexed keywords

CISPLATIN; ETOPOSIDE; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CAUSE OF DEATH; CISPLATIN; DIARRHEA; DISEASE PROGRESSION; ETOPOSIDE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; REMISSION INDUCTION; SURVIVAL RATE;

EID: 0034448436     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200008000-00012     Document Type: Article

References (17)

1. Cancer statistics
2. Lung cancer research: New combinations and the emerging role of gemcitabine
3. An update on North American randomized studies in non-small cell lung cancer
4. Future directions in the management of non-small cell lung cancer
5. New treatment agents for advanced small cell and non-small cell lung cancer
6. Polychemotherapy in advanced non-small cell lung cancer: A meta-analysis
7. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: A Southwest Oncology Group study
8. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: A study of Eastern Cooperative Oncology Group
9. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer protocol 07861
10. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small cell lung carcinoma
11. Cis-diaminedichloroplatinum (II): Combination chemotherapy and cross-resistance studies with tumors of mice
12. 5-Fluorouracil, etoposide, and cisplatin in the management of metastatic non-small cell lung cancer
13. Cisplatin, 5-fluorouracil and etoposide for advanced non-small cell lung cancer
14. A study of oral etoposide, infusional cisplatin, and infusional 5-fluorouracil for locally advanced or metastatic non-small cell lung cancer: A mid-atlantic oncology program study
15. Toxicity of FED chemotherapy in non-small cell lung cancer
16. Phase II pilot study with cisplatin, etoposide, and continuous infusion 5-fluorouracil in metastatic non-small cell lung cancer
17. A phase II study of cisplatin, 5-fluorouracil, leucovorin, and etoposide in advanced non-small cell lung cancer